• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

FDA advisory committee

Photo of a person celebrating at the top of the mountain while the sun setsrises
Biotech

Replimune’s twice-rejected melanoma drug prevails in FDA adcomm

Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of oncolytic virus RP1's effectiveness.
Darren Incorvaia Jul 30, 2026 6:20pm
Question mark made of numbers

FDA adcomm shoots down Capricor's Duchenne cell therapy

Jul 29, 2026 6:06pm
AZ

FDA panel rejects AstraZeneca's novel oral SERD proposal

Apr 30, 2026 1:48pm
FDA

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

Apr 28, 2026 2:47pm
An artists concept of chains of amino acides called peptides which together make up polypeptides or proteins
Favicon Fierce Pharma

FDA advisory committee to discuss action on unapproved peptides

Apr 15, 2026 5:15pm
FDA conference hall

FDA to end 9-month adcomm hiatus with review of AZ cancer drugs

Mar 6, 2026 11:16am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings